Open-label memantine in fragile X syndrome

Craig A. Erickson, Jennifer E. Mullett, Christopher J. McDougle

Research output: Contribution to journalArticle

50 Scopus citations


Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.

Original languageEnglish (US)
Pages (from-to)1629-1635
Number of pages7
JournalJournal of Autism and Developmental Disorders
Issue number12
StatePublished - Dec 1 2009


  • Fragile X syndrome
  • Hyperactivity
  • Inattention
  • Irritability
  • Memantine
  • Social withdrawal

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Fingerprint Dive into the research topics of 'Open-label memantine in fragile X syndrome'. Together they form a unique fingerprint.

  • Cite this